# S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

> **NCT00445601** · PHASE3 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 406 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00445601
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2020-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445601, "S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00445601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*